Rewriting Cancer: AmirAli Talasaz, Co-CEO of Guardant Health, on Liquid Biopsy, Data & Biotech Grit

Synopsis: Some of the most game-changing ideas in healthcare come from unexpected intersections—where engineering meets biology, and where data meets patient urgency. This episode of Biotech 2050 dives into that exact convergence with a look at how one visionary leader helped pioneer blood-based cancer diagnostics. Co-CEO & Co-Founder of Guardant Health, AmirAli Talasaz, shares the story behind building one of biotech’s most impactful companies. From a graduate student navigating genomics for the first time to raising over $3 billion and leading a public company, he reflects on lessons learned, obstacles faced, and what it takes to create a patient-first culture at scale. The conversation explores the technology behind liquid biopsies and companion diagnostics, the challenges of insurance reimbursement, and how Guardant’s innovations are helping detect recurrence and screen for early-stage cancers—all through a simple blood test. Hosted by Biotech 2050 Co-Founder Rahul Chaturvedi, this episode is packed with insights on biotech leadership, pharma partnerships, and building a company that scales with both urgency and heart. Biography: AmirAli Talasaz is the co-CEO of the leading precision oncology company, Guardant Health, which he co-founded in 2012 with Helmy Eltoukhy. Prior to co-founding Guardant Health, he was senior director of Diagnostics Research at Illumina and led the efforts for emerging clinical applications of next-generation genomic analysis. Before Illumina, he founded Auriphex Biosciences, which focused on purification and genetic analysis of circulating tumor cells for cancer management. Talasaz received his PhD in electrical engineering and MSc in management science from Stanford University.

You can listen to Rewriting Cancer: AmirAli Talasaz, Co-CEO of Guardant Health, on Liquid Biopsy, Data & Biotech Grit online on Radio and Podcast. Open the player on this page to stream the available audio.

Rewriting Cancer: AmirAli Talasaz, Co-CEO of Guardant Health, on Liquid Biopsy, Data & Biotech Grit is an episode from Biotech 2050 Podcast by Biotech2050 Podcast.

This episode is 00:39:08 long.

This episode was published on Aug 14, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from Biotech 2050 Podcast when more episodes are available from the podcast feed.